News for Autolus Therapeutics plc (AUTL)

Key Takeaways: Autolus Therapeutics (AUTL) is poised for a significant upside if EMA approval is granted for its leukemia treatment. Analysts project a c

Autolus Therapeutics (AUTL) has received a significant endorsement from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agen

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Autolus Therapeutics plc (NASDAQ:AUTL) was one of the stocks that was covered in that article.

Autolus Therapeutics (AUTL) has shared the online publication of three abstracts for the upcoming European Hematology Association Congress, set for June 12-15,

On March 31, 2025, Syncona Portfolio Ltd (Trades, Portfolio) executed a significant transaction by acquiring an additional 12,180,333 shares of Autolus Therapeu

Autolus Therapeutics plc (NASDAQ:AUTL) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsAmanda Cray – Executive Director-Investor...

The following slide deck was published by Autolus Therapeutics plc in conjunction with their 2025 Q1 earnings call.

Release Date: May 08, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Autolus Therapeut

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NAUTL.OQ - Autolus Therapeutics PLCQ1 2025 Autolus Therapeutics PLC Earnings CallMay 08, 2025 /

**media[618807]**

\nRegulatory News:\n\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (â\u0080\u009cInnateâ\u0080\u009d or the â\u0080\u009cCompanyâ\u0080\u009d) today announced it will propose to its Annual Genera

Operator: Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Call to Discuss the Full Year 2024 Financial Results and Business Updates.

Autolus Therapeutics PLC (AUTL) is set to release its Q4 2024 earnings on Mar 20, 2025. The consensus estimate for Q4 2024 revenue is $1.07 million, and the ear

Cash Equivalents and Marketable Securities: $588 million at year-end 2024, up from $239 million at December 31, 2023.Loss from Operations: $241.4 million for t

Mar 20, 2025 / 12:30PM GMTOperator Hello ladies and gentlemen and welcome to the Autolus Therapeutics call to discuss its full year 2024 financial results and b

Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ETCompany ParticipantsAmanda Cray - IRChristian Itin - CEORob...

The following slide deck was published by Autolus Therapeutics plc in conjunction with their 2024 Q4 earnings call.

AUCATZYL® (obecabtagene autoleucel) U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA app

We recently compiled a list of the 10 Best UK Growth Stocks to Buy Now. In this article, we are going to take a look at where Autolus Therapeutics plc (NASDAQ:AUTL) stands against the other UK growth...